Jennifer Keeley
Adult Health · Wexford, PANPI 1932488046
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (43.1%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 23.9%. 2025 is the largest year on record at $44,493, 6.4 times the $6,972 reported in 2021. Among adult health clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 330 payments — averaging $294.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$23K
- E.r. Squibb & Sons, L.L.C.$21K
- Johnson & Johnson$19K
- Alnylam Pharmaceuticals Inc.$17K
- United Therapeutics Corporation$6K
- Merck$5K
- plus $5K from 10 others
What the payments were for
- Consulting fees$25,17526%
- Speaking & faculty fees$41,88043%
- Travel & lodging$21,33822%
- Food & beverage$8,5869%
- Education$2240%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 72 | $23,266 |
| E.r. Squibb & Sons, L.L.C. | 47 | $20,730 |
| Johnson & Johnson(2 entities) | 56 | $19,401 |
| Alnylam Pharmaceuticals Inc. | 40 | $17,017 |
| United Therapeutics Corporation | 36 | $6,071 |
| Merck | 14 | $5,314 |
| Bridgebio Pharma, Inc. | 8 | $2,439 |
| Bayer | 12 | $1,197 |
| Novartis | 6 | $793 |
| Pfizer | 13 | $237 |
| Amgen | 4 | $208 |
| AstraZeneca | 7 | $156 |
| Novo Nordisk | 3 | $146 |
| Boehringer Ingelheim | 7 | $141 |
| Scpharmaceuticals Inc. | 4 | $68 |
| Vifor Pharma, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$97,203 in reported general payments places this provider in the 95th percentile of 899 adult health providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CamzyosMavacamten | 124 | $1,032,468 |
| VyndamaxTafamidis | 21 | $477,821 |
| EntrestoSacubitril/Valsartan | 102 | $99,166 |
| EliquisApixaban | 68 | $71,462 |
| JardianceEmpagliflozin | 52 | $63,597 |
| Tadalafil | 20 | $44,289 |
| AdcircaTadalafil | 11 | $40,733 |
| FarxigaDapagliflozin Propanediol | 25 | $15,449 |
| Repatha SureclickEvolocumab | 13 | $7,154 |
| Bumetanide | 84 | $2,987 |
| Metoprolol Succinate | 144 | $2,947 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 71 | $2,555 |
| Ranolazine ErRanolazine | 16 | $1,284 |
| Atorvastatin Calcium | 114 | $1,188 |
| Valsartan | 32 | $946 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Camzyos | $20,730 | $1,032,468124 claims |
| PfizerVyndamax, Eliquis | $237 | $549,28389 claims |
| NovartisEntresto | $793 | $99,166102 claims |
| Boehringer IngelheimJardiance | $141 | $63,59752 claims |
| United Therapeutics CorporationAdcirca | $6,071 | $40,73311 claims |
| AstraZenecaFarxiga | $156 | $15,44925 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 899 adult health providers in Pennsylvania.
Other adult health in Wexford
- Beth SandyPhiladelphia$924K
- Jennifer MondilloSchwenksville$396K
- Diane NewmanPhiladelphia$343K
- Elizabeth FaustDouglassville$342K
- Abigail SmithPhiladelphia$302K
- Jean CainAllentown$214K
- Debra EvansFarrell$85K
- Bethann MallonBlue Bell$65K
- Catherine HoldsworthPhiladelphia$64K
- Melissa LaporteWilkes Barre$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.